检查点抑制剂免疫介导反应药物警戒评估
基于FAERS 2011-2015年数据,对伊匹木单抗、纳武利尤单抗和帕博利珠单抗的免疫介导反应进行回顾性药物警戒不一致性分析,发现结肠炎和肺炎信号最强,不同药物信号谱存在差异。
要点
- 结肠炎和肺炎是检查点抑制剂最强的免疫介导反应信号
- 伊匹木单抗以结肠炎信号最强,纳武利尤单抗和帕博利珠单抗以肺炎信号最强
- 不同检查点抑制剂免疫介导反应谱存在差异
核心结论
- 检查点抑制剂治疗与多种免疫介导反应相关,尤其是结肠炎和肺炎。
- 单个检查点抑制剂具有不同的免疫介导反应信号,需药物流行病学研究验证。
研究设计与样本
- 回顾性药物警戒不一致性分析,数据来源于美国FDA不良事件报告系统(FAERS)。
- 分析2011至2015年提交的FAERS不良事件报告,通过通用名识别检查点抑制剂,通过MedDRA首选术语识别免疫介导反应。
主要发现
- 共提交1,018例检查点抑制剂免疫介导反应事件,其中伊匹木单抗占76%、纳武利尤单抗占15%、帕博利珠单抗占9%。
- 免疫介导反应构成:结肠炎51%、内分泌病16%、肺炎12%、肝炎11%、输注相关反应4%、肾炎3%、其他3%。
- 结肠炎分别占伊匹木单抗和纳武利尤单抗免疫介导反应的63%和41%。
- 帕博利珠单抗的免疫介导反应以肺炎和肝炎为主,未报告肾炎和输注相关反应。
- 检查点抑制剂类信号EB05=12.4,伊匹木单抗EB05=13.2、纳武利尤单抗EB05=15.0、帕博利珠单抗EB05=7.3。
关键数值与推荐
- 信号定义为EB05≥2.0。
- 采用经验贝叶斯几何均值及95%置信区间(EB05-EB95)作为检查点抑制剂-免疫介导反应关联指标。
临床怎么用
- 临床使用检查点抑制剂时应重点监测结肠炎和肺炎等免疫介导反应。
- 不同检查点抑制剂的免疫介导反应谱存在差异,监测策略可有所侧重。
局限性
- 数据收集期早于最新批准的检查点抑制剂,无法涵盖其数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: Ipilimumab, pembrolizumab, and nivolumab are checkpoint inhibitors (CPIs) that activate T-cell-mediated immune response. CPI can provide durable benefits to some cancer patients with melanoma, renal cell cancer, non-small cell lung cancer, or a growing list of other cancers. However, CPI treatment is also associated with adverse immune-mediated reactions (IMRs) that can be life-threatening. This pharmacovigilance analysis aims to characterize IMR signals in relation to CPI treatment. DESIGN: Retrospective pharmacovigilance disproportionality analysis. DATA SOURCE: U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). MEASUREMENTS AND MAIN RESULTS: Adverse event reports submitted to FAERS between 2011 and 2015 were analyzed. CPIs were identified by generic names, and IMRs were identified by MedDRA Preferred Terms. Empirical Bayes geometric means with corresponding 95% confidence intervals (EB05-EB95) were calculated as CPI-IMR association metrics. Signals were defined as metrics with EB05 ≥ 2.0. Overall, 1,018 IMR events were submitted for CPIs, corresponding to 76% for ipilimumab, 15% for nivolumab, and 9% for pembrolizumab. The period of data collection precluded data on the most recently approved CPI agents. IMRs consisted of 51% colitis, 16% endocrinopathies, 12% pneumonitis, 11% hepatitis, 4% infusion-related reactions, 3% nephritis, and 3% other IMRs. Colitis contributed to 63% and 41% of IMRs for ipilimumab and nivolumab, respectively. Pneumonitis and hepatitis contributed to a majority of IMRs for pembrolizumab, for which nephritis and infusion-related reactions were not reported. Signals of IMRs were detected for CPIs as a class (EB05 = 12.4) and individual agents: ipilimumab (EB05 = 13.2), nivolumab (EB05 = 15.0), and pembrolizumab (EB05 = 7.3). Colitis and pneumonitis had the strongest signals for CPIs (EB05 = 45.6 and EB05 = 17.6, respectively). Colitis was the strongest signal for ipilimumab (EB05 = 54.2), and pneumonitis was the strongest signal for nivolumab (EB05 = 48.0) and pembrolizumab (EB05 = 21.8). CONCLUSION: Cancer immunotherapy with CPIs is associated with a multitude of IMRs, especially colitis and pneumonitis. Individual CPIs had variable IMR signals, and pharmacoepidemiologic studies are required to evaluate the identified signals.
引用
- Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. Pharmacotherapy. 2017. PMID: 28950039. doi:10.1002/phar.2035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。